Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R, Li Y, Rule S, Furman RR

Open source

DOI: 10.1182/bloodadvances.2025017713
Published: 2026 Jul 28
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025017713,
  title = {Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.},
  author = {Owen RG and McCarthy H and D'Sa S and Thomas SK and Tournilhac O and Forconi F and Kersten MJ and Zinzani PL and Iyengar S and Kothari J and Minnema MC and Kastritis E and Cheson BD and Walter HS and Greenwald D and Calvo R and Li Y and Rule S and Furman RR},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025017713},
  url = {https://doi.org/10.1182/bloodadvances.2025017713}
}

RIS

TY  - JOUR
TI  - Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
AU  - Owen RG
AU  - McCarthy H
AU  - D'Sa S
AU  - Thomas SK
AU  - Tournilhac O
AU  - Forconi F
AU  - Kersten MJ
AU  - Zinzani PL
AU  - Iyengar S
AU  - Kothari J
AU  - Minnema MC
AU  - Kastritis E
AU  - Cheson BD
AU  - Walter HS
AU  - Greenwald D
AU  - Calvo R
AU  - Li Y
AU  - Rule S
AU  - Furman RR
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025017713
UR  - https://doi.org/10.1182/bloodadvances.2025017713
ER  -

APA

RG, O., H, M., S, D., SK, T., O, T., F, F., MJ, K., PL, Z., S, I., J, K., MC, M., E, K., BD, C., HS, W., D, G., R, C., Y, L., S, R., & RR, F. (2026). Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.. Blood advances. https://doi.org/10.1182/bloodadvances.2025017713

Source records

pubmed · retrieved 2026-09-26T18:04:16.055Z